|Title:||Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same|
|Abstract:||The invention relates to novel uracil derivatives having excellent inhibiting effects of human derived thymidine phosphorylase and anti-tumor activity. The pharmaceutical compositions, anti-tumor potentiators, antitumor agents containing such novel compounds, and a process for their preparation and use is described. The novel compounds satisfy the general formula (1): ##STR1##|
|Inventor(s):||Yano; Shingo (Kawagoe, JP), Tada; Yukio (Higashimatsuyama, JP), Kazuno; Hideki (Hanno, JP), Sato; Tsutomu (Hanno, JP), Yamashita; Junichi (Honjo, JP), Suzuki; Norihiko (Hidaka, JP), Emura; Tomohiro (Iruma, JP), Fukushima; Masakazu (Hanno, JP), Asao; Tetsuji (Tokorozawa, JP)|
|Assignee:||Taiho Pharmaceutical Co., Ltd. (Tokyo, JP)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
Field: Basic materials chemistry
Back Citations: 3rd percentile
Forward Citations: 6th percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.